Here is an interesting online free event on 17th of May with Matt Kaeberlein and Richard Miller.
Thanks for the heads up… total respect for Matt Kaeberlein’s cautious optimism using rapamycin. I registered and sent in this question.
The Rapamycin with Acarbose combo has a significant life and health span in clinical mouse trials. Do you believe this would hold true in humans? And, if so a good plan for off label prescribed patients?
Don’t forget this amazing free online event which start within an hour with Matt Kaeberlein and Richard Miller. Registration is done here.
Noon Eastern Time, 9am California/PST. 18:00 CET
Here is the link to the presentation - I wonder if others can just use this, without the hassle of registering:
Rich noted the two most recently successful longevity drugs, papers in process and to be published soon:
Meclizine - 8% increase in lifespan, only males
Astaxanthin - 12%
And Fisetin did not work (one reason for this can be wrong dose regime)
They got feedback on dosing from the top researchers (Kirkland) on the best dose to test regarding Fisetin.
The most interesting part of the talk for me was the discussion on Telomeres.
Richard - no evidence for a role for telomeres in aging. In mice they can shorten the telomere length of mice and no changes in lifespan.
Matt - believes that there is evidence to support a role for telomeres in aging, but it isn’t the biggest factor in aging by a long shot.
Was the event taped?
It seems like the event will be possible to view later on when they publish it on there homepage. I can add the link here when they publish it.
Very exciting. Was the 12% Astaxanthin effect in both males and females?
Re Meclizine, might be important to take this into account: “ This medication may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert. Drinking alcohol can increase certain side effects of meclizine” Meclizine: Uses, Dosage & Side Effects - Drugs.com
Yes - we had an in-depth discussion here when the meclizine data first started to come out… see this thread: Meclizine / Dramamine II, Approx 15% Lifespan Increase, Another mTORC1 Inhibitor
The final data from all three labs is not as good as this information from a single lab.
The issue is that it is an anticholinergic drug, and Meclizine has a score of 3, on the cognitive burden scale, so can increase the risk of dementia. (So this is not looking good in that respect).
Most of us here lost enthusiasm for this drug when you review the literature closely.
Thanks, this is very helpful.
And the Astaxanthin data started coming out last April, and the 12% is only in males. See full discussion here: Astaxanthin: A Potential Treatment in Disease and Aging, Lifespan Increase
Yes, but the questions around Astaxanthin are:
- Which is better - natural or artificial Asta
- Is dosing at low levels effective?
- What dosage level works?
Do they share any preliminary data about compounds from 2020 cohort? (16 alpha-hydroxyestradiol, Hydralazine, etc)
What is overall TLDW?
Here is the recording for viewing it afterwards
Tack ska du ha Krister!
It would be appropriate for Rapamycin News to extend an invitation to Steve Austad and Bill Andrews for an in-depth discussion. The hour has indeed come for us to commence vibrant intellectual exchanges with the vanguards in the longevity field.